Drug
Darolutamide
Darolutamide: highest development phase Post-Market, developed by Bayer, Veracyte. 7 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Bayer, Veracyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| Darolutamide (Nubeqa, BAY1841788) NCT05348876 | Post-Market | Non-metastatic Castration-resistant Prostate Cancer |
| Darolutamide (Nubeqa, BAY1841788) NCT04464226 | Phase 3 | Cancer |
| Darolutamide (Nubeqa, BAY1841788) NCT04736199 | Phase 3 | Prostatic Neoplasms |
| Darolutamide NCT06282588 | Phase 2/3 | Prostate Cancer |
| Darolutamide NCT07450599 | Phase 2 | High-risk Localized Prostate Cancer |
| Darolutamide (BAY1841788, Nubeqa) NCT05059236 | Phase 2 | Metastatic Hormone-sensitive Prostate Cancer |
| darolutamide NCT03004534 | Phase 1 | Breast Cancer Female |
Latest
Follow Darolutamide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.